Abnormal liver function tests in patients with Type 1 diabetes mellitus: Prevalence, clinical correlations and underlying pathologies

Diabetic Medicine

Volumn 26, Issue 12, 2009, Pages 1235-1241

  Leeds, J S ^a   Forman, E M ^a   Morley, S ^a   Scott, A R ^a   Tesfaye, S ^a   Sanders, D S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Aetiology; Hepatic disease; Type 1 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL FEATURE; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; LIVER DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 70549093280     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02839.x     Document Type: Article

References (28)

1. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004 126 : 460 468.
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population-based case control study. Gut 2005 54 : 533 539.
3. Shahib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005 128 : 620 626.
4. De Marco R, Locatelli F, Zoppini G. Cause-specific mortality in type 2 diabetes. Diabetes Care 1999 22 : 756 761.
5. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005 22 : 24 27.
6. Marchesini G, Brizi M, Morselli-Labate A, Blanchi G, Bugianesi E, McCullogh A et al. Association of non-alcoholic fatty liver disease and insulin resistance. Am J Med 1999 107 : 450 455.
7. Matteoni C, Younossi Z, Gramlich T, Bopari N, Liu Y, McCullough N. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 116 : 1413 1419.
8. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999 29 : 664 669.
9. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000 32 : 689 692.
10. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005 28 : 2913 2918.
11. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007 30 : 734 743.
12. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009 104 : 861 867.
13. West J, Brousil J, Gazis A, Jackson L, Mansell P, Bennett A et al. Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. Q J Med 2006 99 : 871 876.
14. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh II. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J 2004 328 : 983 987.
15. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001 35 : 195 199.
16. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999 94 : 3010 3014.
17. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002 137 : 1 10.
18. Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009 29 : 387 396.
19. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008 48 : 792 798.
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007 30 : S42 S47.
21. Mohsen AH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001 48 : 707 713.
22. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006 101 : 76 82.
23. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009 29 : 113 119.
24. Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M et al. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008 31 : 146 152.
25. Diehl AM, Clark JM. Defining non-alcoholic fatty liver disease: implications for epidemiological studies. Gastroenterology 2003 124 : 248 250.
26. Takaike H, Uchigata Y, Iwasaki N, Iwamoto Y. Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract 2004 64 : 27 32.
27. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003 15 : 539 543.
28. McGill M, Molyneaux L, Twigg SM, Yue DK. The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications 2008 22 : 18 23.